MedWatch

Orexo CEO on EU approval: Great need and potential for Zubsolv

The Swedish drug group Orexo, in which Novo Holdings holds parts of the shares, has obtained an approval of its main asset in EU. Zubsolv treats addiction to pain-relieving medicine and according to the company’s Danish CEO, mint taste, multidoses, and shorter resolving time make the drug a potential winner.

Foto: Orexo/PR

Since 2013, the publicly listed Swedish drug group Orexo’s key asset has been sold in the US. The drug is now ready for the EU market, too.

This is clear after the EU Commission approved the new drug application for Zubsolv (buprenorfin og naloxon) that Orexo and the partner Mundipharma filed with the European Medicines Agency (EMA) in 2016.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier